Xin Lang Cai Jing·2025-08-24 13:24Group 1 - The company held an investor relations event via conference call, attracting over 70 institutions including Dongwu Securities and Ping An Securities [1] - The event featured a presentation by the board secretary on the company's performance for the first half of 2025, followed by a Q&A session addressing core products and business development [1] - The company aims to achieve a 30% net profit growth rate by 2025 through stock incentives, focusing on the promotion of its key product, Wuling Capsules, and expanding market share through collective procurement [1] Group 2 - The Bailing series products, including Bailing tablets and capsules, have participated in the national Chinese medicine procurement alliance, with 28 provinces issuing procurement execution notices, expecting a 38.51% year-on-year sales growth in the first half of 2025 [2] - The company is optimizing its market layout and sales team for rapid growth in the Chinese medicine granule business, while the Chinese medicine decoction pieces have shown stable growth after excluding special factors [2] - The company is implementing a multi-dimensional strategy for the C-end market, including organizational optimization, market expansion, O2O online operations, and consumer education to increase C-end sales proportion [2]